Evidence map›Paper›PMID 34832518›Full record

ArticlePathogens (Basel, Switzerland)2021

In-Depth Longitudinal Comparison of Clinical Specimens to Detect SARS-CoV-2.

Justine Defêche, Samira Azarzar, Alyssia Mesdagh, Patricia Dellot, Amandine Tytgat, Fabrice Bureau, Laurent Gillet, Yasmine Belhadj, Sebastien Bontems, Marie-Pierre Hayette and 5 more

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Justine DefêcheDepartment of Clinical Microbiology, University of Liège, 4000 Liège, Belgium.
Samira AzarzarDepartment of Infectious Diseases, Liège University Hospital, 4000 Liège, Belgium.
Alyssia MesdaghDepartment of Infectious Diseases, Liège University Hospital, 4000 Liège, Belgium.
Patricia DellotDepartment of Infectious Diseases, Liège University Hospital, 4000 Liège, Belgium.
Amandine TytgatLaboratory of Cellular and Molecular Immunology, GIGA Institute, University of Liège, 4000 Liège, Belgium.
Fabrice BureauLaboratory of Cellular and Molecular Immunology, GIGA Institute, University of Liège, 4000 Liège, Belgium.
Laurent GilletImmunology-Vaccinology Laboratory, Department of Infectious and Parasitic Diseases, FARAH, University of Liège, 4000 Liège, Belgium.
Yasmine BelhadjDepartment of Infectious Diseases, Liège University Hospital, 4000 Liège, Belgium.ORCID 0000-0002-2040-1309
Sebastien BontemsDepartment of Clinical Microbiology, University of Liège, 4000 Liège, Belgium.
Marie-Pierre HayetteDepartment of Clinical Microbiology, University of Liège, 4000 Liège, Belgium.ORCID 0000-0002-9025-6493
Raphaël SchilsDepartment of Infectious Diseases, Liège University Hospital, 4000 Liège, Belgium.
Souad RahmouniUnit of Animal Genomics, GIGA Institute, University of Liège, 4000 Liège, Belgium.
Marie ErnstBiostatistics and Medico-Economic Information Department, University Hospital of Liege, 4000 Liege, Belgium.ORCID 0000-0002-9002-5783
Michel MoutschenDepartment of Infectious Diseases, Liège University Hospital, 4000 Liège, Belgium.
Gilles DarcisDepartment of Infectious Diseases, Liège University Hospital, 4000 Liège, Belgium.ORCID 0000-0001-8192-1351
University of Liège · BE

Funding

Fonds Léon Fredericq NA. Recipient: Gilles Darcis
6 · The paper itself

Abstract

The testing and isolation of patients with coronavirus disease 2019 (COVID-19) are indispensable tools to control the ongoing COVID-19 pandemic. PCR tests are considered the "gold standard" of COVID-19 testing and mostly involve testing nasopharyngeal swab specimens. Our study aimed to compare the sensitivity of tests for various sample specimens. Seventy-five participants with confirmed COVID-19 were included in the study. Nasopharyngeal swabs, oropharyngeal swabs, Oracol-collected saliva, throat washes and rectal specimens were collected along with pooled swabs. Participants were asked to complete a questionnaire to correlate specific clinical symptoms and the symptom duration with the sensitivity of detecting COVID-19 in various sample specimens. Sampling was repeated after 7 to 10 days (T2), then after 14 to 20 days (T3) to perform a longitudinal analysis of sample specimen sensitivity. At the first time point, the highest percentages of SARS-CoV-2-positive samples were observed for nasopharyngeal samples (84.3%), while 74%, 68.2%, 58.8% and 3.5% of throat washing, Oracol-collected saliva, oropharyngeal and rectal samples tested positive, respectively. The sensitivity of all sampling methods except throat wash samples decreased rapidly at later time points compared to the first collection. The throat washing method exhibited better performance than the gold standard nasopharyngeal swab at the second and third time points after the first positive test date. Nasopharyngeal swabs were the most sensitive specimens for early detection after symptom onset. Throat washing is a sensitive alternative method. It was found that SARS-CoV-2 persists longer in the throat and saliva than in the nasopharynx.

Indexed as

COVID-19diagnosispersistenceSARS-CoV-2

Identifiers

PMID34832518
PMCPMC8622859
OpenAlexW3206159408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.